eLearningClasses.com

Forbion Announces First Close of Forbion Growth Opportunities Fund at EUR 185 Million (USD 208 Million)

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Forbion, a leading European life sciences venture capital firm, today announces the first close at EUR 185 million (USD 208 million) of its new Forbion Growth Opportunities Fund (Forbion Growth”), focused on investing in late-stage European life sciences companies.

Returning investors to the new Forbion fund include Pantheon, KfW Capital and the European Investment Fund (EIF). New investors include Eli Lilly and Company, Horizon Therapeutics plc (Nasdaq: HZNP), Belgian Growth Fund and New Waves Investments.

Forbion Growth will focus on later-stage investments, particularly in European biotech companies developing novel therapies for areas of high medical need. The Fund will target this market segment with three distinct strategies: providing private growth capital for mature clinical development assets, providing pre-IPO funding to companies aiming to pursue a public listing in the near-term and providing capital injections, supporting existing, under-valued public companies. In all cases, Forbion Growth aims to take leading positions with an investment size of up to EUR 30 million per deal.

Forbions strong historical performance and market position in the German market have allowed KfW Capital and EIF to commit to Forbion Growth from their respective ERP facilities, thereby mobilizing smart growth capital for the German life sciences sector. Both KfW Capital and EIF have been long-term supporters of the Forbion family of funds.

In executing its strategy, Forbion Growth will work closely with its newly established Advisory Group, consisting of the most successful and entrepreneurial CEOs and advisors in the European BioPharma space. The Funds Advisory Group consists of Onno van de Stolpe (CEO Galapagos), Jan van de Winkel (CEO Genmab), Tim van Hauwermeiren (CEO Argenx), Werner Lanthaler (CEO Evotec) and Maarten de Jong (Moelis & Co).

Forbion started the fund-raising process for Forbion Growth in February 2020 and expects to complete the Fund by the end of this year. The goal is to raise EUR 250 million and to build a portfolio of 8-12 investments in the most promising European growth-stage life sciences companies.

Sander Slootweg, Managing Partner and co-founder of Forbion said:

The market for late-stage, private European life sciences investments is already sizable at EUR 2 billion per annum and rapidly growing. Despite the de-risked nature of the late-stage clinical assets in these companies, this market segment is still underserved. As a result, many companies and assets stall in late-stage development, due to a lack of specific funding. With our dedicated Growth Fund and specialized team, we are well-positioned to optimally exploit this opportunity and ensure that new, impactful treatments and therapies will make their way to patients and doctors.

With well over EUR 1.25 billion of assets under management, Forbion has been ranked the #1 most consistently performing VC Manager in Europe by Preqins fund performance database. Forbions investment team has built an impressive performance track record with over 66 investments in both the EU and North America over the past 15 years.

Forbion has led the first institutional rounds of several of Europes leading biotech companies such as Argenx (ARGX; market cap USD 10 billion), Uniqure (QURE; market cap USD 2 billion) as well as clinical-stage companies such as Promedior (acquired by Roche for up to EUR 1.4 billion), Dezima Pharma (acquired by Amgen for up to EUR 1.55 billion) and Prexton Therapeutics (acquired by Lundbeck for up to EUR 905 million).

Dirk Kersten, General Partner, added:

We have assembled a world-class team and Advisory Group to manage our new Growth Fund. Wouter Joustra, General Partner, and Anastasia Karpova, Principal, both joined us from Kempen, a leading Life Sciences boutique bank in Europe. In addition, Carlo Incerti, former Chief Medical Officer at Sanofi-Genzyme, and Patrick Vink, former Chief Operating Officer at Cubist Pharmaceuticals, have joined the team as Operating Partners. This very experienced Growth team will work in a fully integrated manner in the broader Forbion organization.

We will be looking to partner with world-class European companies and entrepreneurs to provide both capital and expertise, building the next generation of successful European Life Sciences companies.

– ENDS –

Notes for Editors:

About Forbion

Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbions investment team has built an impressive performance track record since the late nineties with successful investments in over 66 companies. Forbion manages well over EUR 1.25 billion across ten funds.

Forbion is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients.

Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI), AMUF and EFSI facilities and KfW Capital through the Programme, ERP “ Venture Capital Fondsinvestments.

Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.

For more information, please visit: www.forbion.com.

Forbion

Sander Slootweg, Managing Partner

P: +31 (0) 35 699 30 00

Instinctif Partners (media)

Ross Gillam / Lewis Hill (Private Equity)

P: +44 7580 816 916

Melanie Toyne-Sewell/Phil Marriage (Life Sciences)

P: +44 (0) 7890 022 814 / +44 (0) 79644 79544

E: [email protected]